Anita R Peoples1, Sheila N Garland2, Wilfred R Pigeon3, Michael L Perlis4, Julie Rya Wolf5, Kathi L Heffner6, Karen M Mustian7, Charles E Heckler7, Luke J Peppone7, Charles S Kamen7, Gary R Morrow7, Joseph A Roscoe7. 1. Clinical and Translational Science Institute, University of Rochester Medical Center, Rochester, New York. 2. Departments of Psychology and Oncology, Memorial University, Newfoundland, Canada. 3. Departments of Psychiatry and Public Health Sciences, University of Rochester Medical Center, Rochester, New York. 4. Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania. 5. Departments of Dermatology and Radiation Oncology, University of Rochester Medical Center, Rochester, New York. 6. School of Nursing and Department of Psychiatry, University of Rochester Medical Center, Rochester, New York. 7. Department of Surgery, University of Rochester Medical Center, Rochester, New York.
Abstract
STUDY OBJECTIVES: The current archival analyses examine the direct and indirect effects of cognitive behavioral therapy for insomnia (CBT-I) on depression in cancer survivors. METHODS: We report on 67 cancer survivors from a 2 × 2 randomized controlled trial of CBT-I and armodafinilfor insomnia, after collapsing across the noneffective study medication conditions (armodafinil/placebo) to create CBT-I (yes/no). Depression and insomnia were assessed before, during the 7-week CBT-I intervention, at postintervention, and 3 months later by the Patient Health Questionnaire and the Insomnia Severity Index, respectively. RESULTS:Mean depression at baseline for all participants was 6.44 (standard error = 0.41, range 0-15). Paired t tests showed that depression improved from baseline to postintervention by 48% (P < .001) in the CBT-I group versus 15% (P = .016) in the non-CBT-I group. Analysis of covariance controlling for baseline found that participants receiving CBT-I had significantly less depression at postintervention (effect size = -0.62; P = .001), compared to those who did not receive CBT-I. These benefits were maintained at the 3-month follow-up. Spearman rank correlations showed that changes in insomnia severity from baseline to postintervention were significantly correlated with concurrent changes in depression (r = .73; P < .001). Path analysis revealed that improvement in depression was mediated by improvement in insomnia severity (P < .001). CONCLUSIONS: Our findings provide preliminary support that in cancer survivors, CBT-I reduces depression via improvement in insomnia. Further, this reduction in depression remained stable 3 months after completing CBT-I. This suggests that a CBT-I intervention has a meaningful effect on depression. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Title: Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy; Identifier: NCT01091974; URL: https://clinicaltrials.gov/ct2/show/record/NCT01091974.
RCT Entities:
STUDY OBJECTIVES: The current archival analyses examine the direct and indirect effects of cognitive behavioral therapy for insomnia (CBT-I) on depression in cancer survivors. METHODS: We report on 67 cancer survivors from a 2 × 2 randomized controlled trial of CBT-I and armodafinil for insomnia, after collapsing across the noneffective study medication conditions (armodafinil/placebo) to create CBT-I (yes/no). Depression and insomnia were assessed before, during the 7-week CBT-I intervention, at postintervention, and 3 months later by the Patient Health Questionnaire and the Insomnia Severity Index, respectively. RESULTS: Mean depression at baseline for all participants was 6.44 (standard error = 0.41, range 0-15). Paired t tests showed that depression improved from baseline to postintervention by 48% (P < .001) in the CBT-I group versus 15% (P = .016) in the non-CBT-I group. Analysis of covariance controlling for baseline found that participants receiving CBT-I had significantly less depression at postintervention (effect size = -0.62; P = .001), compared to those who did not receive CBT-I. These benefits were maintained at the 3-month follow-up. Spearman rank correlations showed that changes in insomnia severity from baseline to postintervention were significantly correlated with concurrent changes in depression (r = .73; P < .001). Path analysis revealed that improvement in depression was mediated by improvement in insomnia severity (P < .001). CONCLUSIONS: Our findings provide preliminary support that in cancer survivors, CBT-I reduces depression via improvement in insomnia. Further, this reduction in depression remained stable 3 months after completing CBT-I. This suggests that a CBT-I intervention has a meaningful effect on depression. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Title: Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy; Identifier: NCT01091974; URL: https://clinicaltrials.gov/ct2/show/record/NCT01091974.
Authors: Michael R Irwin; Richard Olmstead; Elizabeth C Breen; Tuff Witarama; Carmen Carrillo; Nina Sadeghi; Jesusa M G Arevalo; Jeffrey Ma; Perry Nicassio; Richard Bootzin; Steve Cole Journal: Biol Psychiatry Date: 2015-02-04 Impact factor: 13.382
Authors: A M H Krebber; L M Buffart; G Kleijn; I C Riepma; R de Bree; C R Leemans; A Becker; J Brug; A van Straten; P Cuijpers; I M Verdonck-de Leeuw Journal: Psychooncology Date: 2013-09-16 Impact factor: 3.894
Authors: Ingrid Tonning Olsson; Margaret M Lubas; Chenghong Li; Belinda N Mandrell; Pia Banerjee; Carrie R Howell; Kirsten K Ness; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull; Tara M Brinkman Journal: JNCI Cancer Spectr Date: 2020-02-19
Authors: Kelly E Rentscher; Judith E Carroll; Mark B Juckett; Christopher L Coe; Aimee T Broman; Paul J Rathouz; Peiman Hematti; Erin S Costanzo Journal: J Natl Cancer Inst Date: 2021-10-01 Impact factor: 13.506
Authors: Alexander J Scott; Thomas L Webb; Marrissa Martyn-St James; Georgina Rowse; Scott Weich Journal: Sleep Med Rev Date: 2021-09-23 Impact factor: 11.609